Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Herz
|
June 20, 2007
A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction
Mark Lamotte, Lieven Annemans, Pawel Kawalec, et al.
Pharmacoeconomics
|
August 11, 2006
A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction
Mark Lamotte, Lieven Annemans, Pawel Kawalec, et al.
Value in Health Regional Issues
|
October 28, 2017
Drug Policy in Poland
Karina Jahnz-Różyk, Pawel Kawalec, Krzysztof Malinowski, et al.
Expert Review of Anticancer Therapy
|
October 14, 2016
Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib
Pawel Kawalec, Iwona Malinowska-Lipień, Tomasz Brzostek, et al.
Frontiers in Pharmacology
|
August 5, 2022
How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
Alessandra Blonda, Yvonne Denier, Isabelle Huys, et al.
Frontiers in Pharmacology
|
March 25, 2024
Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
Szczepan Jakubowski, Pawel Kawalec, Przemyslaw Holko, et al.
Orphanet Journal of Rare Diseases
|
November 7, 2018
The European challenges of funding orphan medicinal products
Márta Szegedi, Tamás Zelei, Francis Arickx, et al.
Frontiers in Pharmacology
|
August 7, 2018
Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
Maria Kamusheva, Manoela Manova, Alexandra T Savova, et al.
Frontiers in Pharmacology
|
September 18, 2025
EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia
Magdalena Monica, Sabina Becirovic, Ioana Bianchi-Manaila, et al.
Health Systems in Transition
|
December 9, 2016
Pharmaceutical regulation in 15 European countries review
Dimitra Panteli, Francis Arickx, Irina Cleemput, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Herz
|
June 20, 2007
A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction
Mark Lamotte, Lieven Annemans, Pawel Kawalec, et al.
Pharmacoeconomics
|
August 11, 2006
A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction
Mark Lamotte, Lieven Annemans, Pawel Kawalec, et al.
Value in Health Regional Issues
|
October 28, 2017
Drug Policy in Poland
Karina Jahnz-Różyk, Pawel Kawalec, Krzysztof Malinowski, et al.
Expert Review of Anticancer Therapy
|
October 14, 2016
Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib
Pawel Kawalec, Iwona Malinowska-Lipień, Tomasz Brzostek, et al.
Frontiers in Pharmacology
|
August 5, 2022
How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
Alessandra Blonda, Yvonne Denier, Isabelle Huys, et al.
Frontiers in Pharmacology
|
March 25, 2024
Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
Szczepan Jakubowski, Pawel Kawalec, Przemyslaw Holko, et al.
Orphanet Journal of Rare Diseases
|
November 7, 2018
The European challenges of funding orphan medicinal products
Márta Szegedi, Tamás Zelei, Francis Arickx, et al.
Frontiers in Pharmacology
|
August 7, 2018
Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
Maria Kamusheva, Manoela Manova, Alexandra T Savova, et al.
Frontiers in Pharmacology
|
September 18, 2025
EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia
Magdalena Monica, Sabina Becirovic, Ioana Bianchi-Manaila, et al.
Health Systems in Transition
|
December 9, 2016
Pharmaceutical regulation in 15 European countries review
Dimitra Panteli, Francis Arickx, Irina Cleemput, et al.
Page
of 1